Patents by Inventor Chi-Fang Wu

Chi-Fang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11072787
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 27, 2021
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Publication number: 20200408962
    Abstract: An electronic device is disclosed, which includes: a panel, including: a first substrate; a second substrate, disposed opposite to the first substrate; a first protection element, disposed on a surface of the first substrate away from the second substrate; and a first polarizer, disposed on the first protection element.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Chi-Fang WU, Chin-Lung TING, I-Chang LIANG
  • Patent number: 10809422
    Abstract: A method for manufacturing an electronic device is disclosed, which includes the following steps: assembling a first mother substrate and a second mother substrate; disposing a first protection element on a surface of the first mother substrate away from the second mother substrate; disposing a first mother polarizer on the first protection element; and processing an assembly of the first mother substrate, the second mother substrate, the first protection element, and the first mother polarizer into a plurality of panels.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: October 20, 2020
    Assignee: Innolux Corporation
    Inventors: Chi-Fang Wu, Chin-Lung Ting, I-Chang Liang
  • Publication number: 20200283751
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: April 7, 2020
    Publication date: September 10, 2020
    Inventors: Chi-Fang WU, Darin LEE, Jeffry D. WATKINS, Kristi PIEHL, Kyle P. CHIANG, Marc THOMAS, Minh-Ha DO, Ying BUECHLER, John D. MENDLEIN
  • Patent number: 10711260
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 14, 2020
    Assignee: aTyr Pharma, Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Publication number: 20200149028
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: September 20, 2019
    Publication date: May 14, 2020
    Inventors: Chi-Fang WU, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Publication number: 20200096673
    Abstract: A method for manufacturing an electronic device is disclosed, which includes the following steps: assembling a first mother substrate and a second mother substrate; disposing a first protection element on a surface of the first mother substrate away from the second mother substrate; disposing a first mother polarizer on the first protection element; and processing an assembly of the first mother substrate, the second mother substrate, the first protection element, and the first mother polarizer into a plurality of panels.
    Type: Application
    Filed: September 26, 2018
    Publication date: March 26, 2020
    Inventors: Chi-Fang WU, Chin-Lung TING, I-Chang LIANG
  • Patent number: 10472618
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 12, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Publication number: 20190062720
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: September 5, 2018
    Publication date: February 28, 2019
    Inventors: Chi-Fang WU, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Patent number: 10093915
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: October 9, 2018
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Patent number: 9822353
    Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 21, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
  • Patent number: 9816084
    Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 14, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Kristi Helen Piehl, Jeffrey Greve, John D. Mendlein
  • Publication number: 20170267990
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: January 25, 2017
    Publication date: September 21, 2017
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Patent number: 9714419
    Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: July 25, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein
  • Patent number: 9688978
    Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: June 27, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
  • Patent number: 9587235
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 7, 2017
    Assignee: aTyr Pharma, Inc.
    Inventors: Ying Buechler, Kyle Chiang, Minh-Ha Do, Darin Lee, Kristi Piehl, Marc Thomas, Jeffry D. Watkins, Chi-Fang Wu, John D. Mendlein
  • Publication number: 20150159148
    Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
    Type: Application
    Filed: December 6, 2012
    Publication date: June 11, 2015
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
  • Publication number: 20140349369
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 27, 2014
    Inventors: Ying Buechler, Kyle Chiang, Minh-Ha Do, Darin Lee, Kristi Piehl, Marc Thomas, Jeffry D. Watkins, Chi-Fang Wu, John D. Mendlein
  • Publication number: 20140335087
    Abstract: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides.
    Type: Application
    Filed: December 27, 2012
    Publication date: November 13, 2014
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Jeffrey D. Watkins, John D. Mendlein
  • Publication number: 20140302075
    Abstract: The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 9, 2014
    Inventors: Ying Ji Buechler, Chi-Fang Wu, Ryan Andrew Adams, Kristi Helen Piehl, Jeffrey Greve, John D. Mendlein